[AstraZeneca’s Novel Pulmonary Therapy Shows Significant Reduction in COPD Exacerbations in Late-Stage Clinical Trials]
AstraZeneca’s novel pulmonary therapy demonstrated a substantial decline in acute COPD exacerbations during phase 3 clinical testing, revealing strong potential for patients facing potentially life‑threatening events of lung dysfunction. Phase 3 trial findings indicated approximately a 30% reduction in COPD exacerbation rates among participants over a one‑year period, marking a promising development for the debilitating condition.
The Phase 3 studies of the injected formulation, nicknamed “tozo” by clinicians, delivered encouraging results that reflect continued strength behind AstraZeneca despite recent setbacks with certain major therapeutic programs. Projected revenue could exceed billions annually across both COPD and complementary indications such as asthma, where the drug’s efficacy profile offers additional market opportunity.
“The data presented at the European Respiratory Society’s annual conference in Barcelona and published in the New England Journal of Medicine shows that tozokimab significantly reduces exacerbations—any sudden worsening requiring medical care, such as severe coughing or breathlessness—by roughly 30% across the full participant cohort over a year.”
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Already have an account? Log in
To read the rest of this story subscribe to STAT+. Subscribe
Also Read
- AstraZeneca COPD Therapy Shows Strong Efficacy in Late‑Stage Trials, FDA Finalizes Key Leadership Appointments
- FDA Targets March 2027 Decision for Lonvo‑Z, the First One‑Time In Vivo CRISPR Therapy for Hereditary Angioedema
- Community Groups Bridge the Gap on Health Coverage for Musicians Across the U.S.
- Mifepristone Safety Review Remains Open as Senators Question All Three Approved Manufacturers